Xianruida Medical-B (06669) issues a profit warning, expecting a mid-term net loss not to exceed 80.9 million yuan, turning from profit to loss year-on-year.

Zhiyu Finance APP News, Xianruida Medical-B (06669) announced that the Group expects to record a net loss of no more than RMB 80.9 million for the six months ending June 30, 2026 (the relevant period), compared to a net profit of approximately RMB 88.6 million for the six months ending June 30, 2025 (the prior period). The expected performance will shift from a net profit in the prior period to a net loss in the relevant period, primarily due to the termination of the AcoArt Litos Paclitaxel-coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (the product) clinical trial in the United States, which has resulted in a one-time non-cash impairment loss (i.e., the capitalized research and development expenses of the clinical project) and a one-time expense provision related to the termination of the clinical project, totaling approximately RMB 151 million. Following a review by management, the Group has terminated the clinical project, considering that changes in the future product pipeline and dynamics of the local U.S. market may limit the profitability of the product; management believes it is commercially preferable to allocate resources to other future product pipelines. The Group is exploring new overseas pipelines with its business partners and will provide further details at the appropriate time.